JP2024533427A5 - - Google Patents
Info
- Publication number
- JP2024533427A5 JP2024533427A5 JP2024515579A JP2024515579A JP2024533427A5 JP 2024533427 A5 JP2024533427 A5 JP 2024533427A5 JP 2024515579 A JP2024515579 A JP 2024515579A JP 2024515579 A JP2024515579 A JP 2024515579A JP 2024533427 A5 JP2024533427 A5 JP 2024533427A5
- Authority
- JP
- Japan
- Prior art keywords
- fatty acid
- group
- acid portion
- gtfa
- conjugate according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163242679P | 2021-09-10 | 2021-09-10 | |
| US63/242,679 | 2021-09-10 | ||
| PCT/US2022/076198 WO2023039522A1 (en) | 2021-09-10 | 2022-09-09 | Fatty acid conjugates of nucleic acids |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024533427A JP2024533427A (ja) | 2024-09-12 |
| JP2024533427A5 true JP2024533427A5 (enExample) | 2025-09-16 |
Family
ID=83508900
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024515579A Pending JP2024533427A (ja) | 2021-09-10 | 2022-09-09 | 核酸の脂肪酸コンジュゲート |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240247274A1 (enExample) |
| EP (1) | EP4398939A1 (enExample) |
| JP (1) | JP2024533427A (enExample) |
| CN (1) | CN117980003A (enExample) |
| CA (1) | CA3231700A1 (enExample) |
| WO (1) | WO2023039522A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018213697A1 (en) * | 2017-05-19 | 2018-11-22 | Band Therapeutics, Llc | Compositions and methods for the treatment of complications and disorders relating to von willebrand factor |
| EP4316495A4 (en) * | 2021-03-25 | 2025-12-31 | Aptacure Therapeutics Ltd | CONJUGATE OF NUCLEIC ACID MOLECULE HAVING A PROLONGED IN VIVO HALF-LIFE |
| WO2025140190A1 (en) * | 2023-12-25 | 2025-07-03 | Microbio (Shanghai) Co., Ltd. | Carbon chain-modified nucleic acids and uses thereof for bacterial cell delivery |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3687808A (en) | 1969-08-14 | 1972-08-29 | Univ Leland Stanford Junior | Synthetic polynucleotides |
| ES2259800T3 (es) | 1990-06-11 | 2006-10-16 | Gilead Sciences, Inc. | Procedimientos de uso de ligandos de acido nucleico. |
| US6682886B1 (en) | 1994-04-28 | 2004-01-27 | Gilead Sciences, Inc. | Bivalent binding molecules of 7 transmembrane G protein-coupled receptors |
| US10588980B2 (en) * | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| KR20190123351A (ko) * | 2017-03-22 | 2019-10-31 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 개질된 올리고뉴클레오티드 및 이의 치료 용도 |
| WO2021046497A2 (en) * | 2019-09-06 | 2021-03-11 | Shen Haifa | Orally delivered therapeutical composition and use thereof |
| IL293341B1 (en) * | 2019-11-26 | 2026-04-01 | Dtx Pharma Inc | A compound comprising a nucleic acid and a half-life extension motif |
| US20230038761A1 (en) * | 2020-02-04 | 2023-02-09 | Band Therapeutics, Llc | Regulation of von willebrand factor (vwf) |
| WO2022058386A1 (en) * | 2020-09-16 | 2022-03-24 | Astrazeneca Ab | Oligonucleotides conjugated to fatty acids |
-
2022
- 2022-09-09 WO PCT/US2022/076198 patent/WO2023039522A1/en not_active Ceased
- 2022-09-09 CA CA3231700A patent/CA3231700A1/en active Pending
- 2022-09-09 EP EP22783243.3A patent/EP4398939A1/en active Pending
- 2022-09-09 JP JP2024515579A patent/JP2024533427A/ja active Pending
- 2022-09-09 CN CN202280060991.5A patent/CN117980003A/zh active Pending
-
2024
- 2024-03-08 US US18/599,808 patent/US20240247274A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024533427A5 (enExample) | ||
| JP5583667B2 (ja) | 長時間作用型ｄｎａデンドリマーおよびその方法 | |
| JP2019048887A (ja) | 製剤用化合物 | |
| JP2022501064A5 (enExample) | ||
| US20070066551A1 (en) | Aptamer medicinal chemistry | |
| ES2605618T3 (es) | ARN de doble cadena, modificado con lípidos con elevado efecto de interferencia por ARN | |
| JP2012509366A5 (enExample) | ||
| WO2007056861A1 (en) | Sirna silencing of influenza virus gene expression | |
| AR079745A1 (es) | Lipidos, composiciones de lipido, metodo de tratamiento y kit | |
| RU2016103695A (ru) | СВЯЗАННАЯ С РЕСПИРАТОРНЫМ ЗАБОЛЕВАНИЕМ ГЕН-СПЕЦИФИЧЕСКАЯ миРНК, ДВУСПИРАЛЬНАЯ КОНСТРУКЦИЯ ОЛИГО-РНК, СОДЕРЖАЩАЯ миРНК, И СОДЕРЖАЩАЯ ЕЕ КОМПОЗИЦИЯ ДЛЯ ПРЕДУПРЕЖДЕНИЯ ИЛИ ЛЕЧЕНИЯ РЕСПИРАТОРНОГО ЗАБОЛЕВАНИЯ | |
| AU2003294437A1 (en) | Multivalent aptamer therapeutics with improved pharmacodynamic properties and methods of making and using the same | |
| JP2013520460A5 (enExample) | ||
| RU2011150787A (ru) | КОНЪЮГАТ миРНК И СПОСОБ ЕГО ПОЛУЧЕНИЯ | |
| JP2023537798A5 (enExample) | ||
| JP2011516094A5 (enExample) | ||
| JPWO2019074110A1 (ja) | 一本鎖核酸分子およびその製造方法 | |
| ES3030929T3 (en) | Arnatar compounds and methods for enhanced cellular uptake | |
| Habus et al. | Synthesis, Hybridization Properties, Nuclease Stability, and Cellular Uptake of the Oligonucleotide-Amino-. beta.-cyclodextrins and Adamantane Conjugates | |
| JP2023504186A5 (enExample) | ||
| JP2024533427A (ja) | 核酸の脂肪酸コンジュゲート | |
| JPWO2005078084A1 (ja) | ２本鎖オリゴ核酸を担持したポリイオンコンプレックスおよびその製造法とそれを含む医薬組成物 | |
| US20130079383A1 (en) | Lipid Compounds Targeting VLA-4 | |
| JP2023172954A5 (enExample) | ||
| IL321125A (en) | Analogues of bicyclic abasic nucleic acids and oligomeric compounds prepared therefrom | |
| CA3179016A1 (en) | Double-stranded oligonucleotide and composition for treating covid-19 containing same |